April 5, 2022 — IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology, and the University Medical Center Groningen (UMCG) announce today a four-year research collaboration agreement towards development of a new FLASH irradiation protocol for the treatment of early-stage breast cancer.
The focus of the partnership will be on building advanced FLASH irradiation techniques and pre-clinical radiobiology models to accelerate the validation and adoption of IBA’s ConformalFLASH[1] technology for use in pre-operative early breast cancer treatment. ConformalFLASH is a novel delivery technique combining ultra-high dose rate FLASH radiotherapy with the unique Bragg Peak properties of protons. These ultra-high dose rates create the opportunity to optimize and accelerate the radiotherapy process and increase the therapeutic ratio[2]. By increasing the fraction dose and applying FLASH dose rates it is hoped that maximal ablative radiotherapy can be delivered.
The delivery of ablative doses of radiation to a tumor is often limited by radiation-induced toxicity to normal surrounding tissues. As a result, the standard of care in breast cancer treatment is to deliver post-operative radiotherapy over multiple doses. In recent years there has been increased interest in applying pre-operative radiotherapy with reduced irradiated volume, whilst increasing the fraction dose, resulting in fewer fractions and thereby improving patient comfort.[3] Furthermore, pre-operative radiotherapy provides the opportunity to study the biological response of breast cancer to radiotherapy.
As part of the collaboration, both parties will share resources and combine expertise as well as leverage the knowledge and infrastructure of the Particle Therapy Research Center (PARTREC), a dedicated research facility functioning in synergy with the clinical UMCG Groningen Proton Therapy Center (GPTC).
Nicolas Denef, Proton Therapy Product Management Director at IBA, added: “We have been working closely with UMCG for many years, following the first flash irradiation in an IBA gantry treatment room in 2019. Our ConformalFLASH technology combines the use of the Proton Bragg Peak with FLASH dose rates, thereby potentially leading to better outcomes. We look forward to once again partnering with UMCG and to sharing this expertise with our large community of IBA centers as this research is conducted.”
Prof. Dr. Stefan Both, Head of Medical Physics at UMC Groningen, said: “We are excited to leverage the combined strength of PARTREC and GPTC to embark on this long-term collaboration with IBA. We hope that through this research, we are able to accelerate patient access to FLASH therapy across the world, to further improve survival rates and quality of life.”
John Maduro, MD, PhD, Radiation Oncologist at UMC Groningen, said: “FLASH proton therapy gives a unique opportunity to explore personalized breast cancer radiotherapy and holds the potential to further reduce treatment burden and cost by offering a single fraction ablative treatment for early-stage breast cancer patients.”
For more information: www.iba-worldwide.com
December 03, 2025 
